One patient died of respiratory failure in a Phase I study of Lyell Immunopharma’s investigational CAR-T therapy. The company on Wednesday said it has not definitively linked the fatality to the treatment.
Today the company announced that its respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months.
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.
“Sarepta is well prepared and uniquely positioned to make this expanded launch a success with four successful launches and compounded annual revenue growth of 115% from the beginning of 2017,” Sarepta CEO Douglas Ingram said on an investor call.
The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue.
China has approved the use of AstraZeneca’s blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said today.